Long-Term MC4R Agonist Treatment in POMC-Deficient Patients

N Engl J Med. 2022 Sep 1;387(9):852-854. doi: 10.1056/NEJMc2207442.
No abstract available

Publication types

  • Letter

MeSH terms

  • Deficiency Diseases* / drug therapy
  • Humans
  • Obesity
  • Pro-Opiomelanocortin* / deficiency
  • Receptor, Melanocortin, Type 4* / therapeutic use
  • alpha-MSH

Substances

  • MC4R protein, human
  • Receptor, Melanocortin, Type 4
  • alpha-MSH
  • Pro-Opiomelanocortin